| 摘要 |
The invention relates to a method for monitoring and/or assessing the tolerability of levosimendan administration, particularly oral administration, in patients. The method comprises determining the plasma level of the active metabolite (II) of a patient after levosimendan administration. Levosimendan is useful in the treatment of congestive heart failure. |
